US Senate tie-break vote on Rx plan

4 April 2001

The US Senate has voted for a Republican amendment to the fiscal 2002budget resolution which would permit spending on Medicare reform and a prescription drug benefit of up to $300 billion over 10 years. However, this would be dependent on the Senate Finance Committee reporting a bill, and that this amount would be no higher that the estimate contained in the new proposal expected from President George W Bush.

The Senate vote was actually tied 50-50, but Vice President Dick Cheney used his tie-breaking vote to pass the amendment, which was proposed by Senate Finance Committee chairman Charles Grassley.

An amendment to the budget resolution proposed by the Democrats failed, also on a tied vote. This would have reduced Pres Bush's proposed $1,600 billion tax cut by about 10%, and increased Medicare spending from $153 billion to $311 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight